GATA2 and acute myeloid leukemia: MDS1‐EVI1 complex (MECOM) rearrangements, which involve the GATA2 gene, have been identified as an adverse risk factor in AML based on the 2022 European LeukemiaNet risk stratification.12, 39, 40, 41